Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewFasentin is a GLUT1 and GLUT4 inhibitor (IC50 = 68 μM). Preferentially inhibits GLUT4 over GLUT1. Sensitizes Fas receptor in a range of tumor cell lines (IC50 = 20 μM) by modulating the extrinsic apoptotic pathway downstream of TNF receptors but upstream of effector caspases.
分子量 | 279.64 |
公式 | C11H9ClF3NO2 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 392721-37-8 |
PubChem ID | 879520 |
InChI Key | GNYIJZMBLZXJEJ-UHFFFAOYSA-N |
Smiles | CC(CC(NC1=CC(C(F)(F)F)=C(C=C1)Cl)=O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Schimmer et al (2006) Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer.Res. 66 2367 PMID: 16489043
Wood et al (2008) A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol.Cancer.Ther. 7 3546 PMID: 19001437
Granchi et al (2016) Anticancer agents interacting with membrane glucose transporters. Med.Chem.Comm. 7 1716 PMID: 28042452
关键词: Fasentin, Fasentin supplier, Fasentin, Inhibitors, Inhibits, Glucose, transporter, GLUT1, GLUT4, Fas-sensitizer, apoptosis, TNF, Transporters, 6100, Tocris Bioscience
目前没有该产品的评论。 Be the first to review Fasentin and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.